MCID: CRN030
MIFTS: 49

Coronary Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 55 44 15 17 72
Coronary Artery Stenosis 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:4248
MeSH 44 D023921
NCIt 50 C80427
UMLS 72 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to hyperlipoproteinemia, type iii and aortic disease, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Lipoprotein metabolism and Ca, cAMP and Lipid Signaling. The drugs Nitric Oxide and Isosorbide Dinitrate have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and homeostasis/metabolism

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia, type iii 30.8 CETP APOE APOB APOA1
2 aortic disease 30.5 IL6 CRP APOE
3 carotid stenosis 30.5 CRP APOE ACE
4 inferior myocardial infarction 30.5 PIK3C2A NPPB
5 anterolateral myocardial infarction 30.5 NPPB ACE
6 angina pectoris 30.4 PIK3C2A NPPB IL6 CRP ACE
7 kawasaki disease 30.4 NPPB IL6 CRP ALB
8 aortic valve insufficiency 30.3 PON1 NPPB ACE
9 atrial standstill 1 30.2 TNNI3 NPPB ACE
10 left bundle branch hemiblock 30.2 TNNI3 NPPB ACE
11 pericarditis 30.1 NPPB IL6 CRP
12 infective endocarditis 30.1 TNNI3 SERPINE1 IL6 CRP
13 aortic atherosclerosis 30.0 PON1 CETP APOE ACE
14 aortic valve disease 2 30.0 VWF NPPB CRP ACE
15 intermediate coronary syndrome 29.9 VWF TNNI3 PIK3C2A IL6 CRP ACE
16 takayasu arteritis 29.9 VWF PON1 IL6 CRP
17 endocarditis 29.9 TNNI3 PIK3C2A IL6 CRP ALB
18 cardiogenic shock 29.9 PIK3C2A NPPB IL6
19 deficiency anemia 29.8 PON1 IL6 CRP ALB
20 cardiac arrest 29.8 PIK3C2A NPPB ALB ACE
21 vasculitis 29.7 VWF ICAM1 CRP
22 heart valve disease 29.7 VWF NPPB CRP ACE
23 pericardial effusion 29.6 PIK3C2A NPPB IL6 CRP
24 atrial fibrillation 29.6 VWF NPPB CRP ACE
25 coronary restenosis 29.6 CETP ACE
26 carotid artery disease 29.5 CRP APOE APOB APOA1 ACE
27 myocarditis 29.4 TNNI3 NPPB IL6 ICAM1
28 proteasome-associated autoinflammatory syndrome 1 29.4 IL6 ICAM1 CRP ALB
29 kidney disease 29.2 SERPINE1 NPPB IL6 CRP APOE ALB
30 end stage renal failure 29.2 IL6 CRP APOB ALB ACE
31 lipid metabolism disorder 29.1 SERPINE1 CRP CETP APOE APOB APOA1
32 aortic valve disease 1 29.1 VWF TNNI3 NPPB CRP APOB ACE
33 pulmonary embolism 28.9 VWF TNNI3 SERPINE1 NPPB CRP ALB
34 dilated cardiomyopathy 28.8 TNNI3 NPPB IL6 CRP ALB ACE
35 pulmonary edema 28.7 PIK3C2A NPPB ICAM1 CRP ACE
36 stroke, ischemic 28.6 VWF SERPINE1 PON1 CRP APOE APOB
37 peripheral artery disease 28.5 PCSK9 IL6 CRP APOB ACE
38 body mass index quantitative trait locus 11 28.5 SERPINE1 PON1 IL6 CRP CETP APOE
39 systemic lupus erythematosus 28.4 VWF IL6 ICAM1 CRP ALB ACE
40 coronary heart disease 1 28.1 SERPINE1 PON1 NPPB IL6 CRP CETP
41 peripheral vascular disease 28.1 VWF SERPINE1 IL6 CRP APOB APOA1
42 acute myocardial infarction 28.1 VWF TNNI3 SERPINE1 PIK3C2A NPPB CRP
43 coronary artery anomaly 28.0 TNNI3 SERPINE1 PON1 PIK3C2A NPPB CRP
44 atherosclerosis susceptibility 27.9 SERPINE1 PON1 IL6 ICAM1 CRP CETP
45 hypertension, essential 27.9 VWF SERPINE1 NPPB APOB APOA1 ALB
46 diabetes mellitus 27.6 SERPINE1 PON1 PIK3C2A IL6 CRP APOB
47 arteriosclerosis 27.5 SERPINE1 PON1 IL6 ICAM1 CRP APOE
48 vascular disease 27.2 VWF SERPINE1 PON1 IL6 CRP CETP
49 cerebrovascular disease 27.1 VWF SERPINE1 PON1 IL6 ICAM1 CRP
50 diabetes mellitus, noninsulin-dependent 26.9 VWF SERPINE1 PON1 IL6 CRP CETP

Graphical network of the top 20 diseases related to Coronary Stenosis:



Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:


angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.02 APOA1 APOB APOE CETP PCSK9

MGI Mouse Phenotypes related to Coronary Stenosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ACE ALB APOA1 APOB APOE CPB2
2 cardiovascular system MP:0005385 10.18 ACE APOA1 APOB APOE CRP ICAM1
3 immune system MP:0005387 10.02 ACE APOB APOE CPB2 CRP ICAM1
4 mortality/aging MP:0010768 9.9 ACE ALB APOB APOE CPB2 ICAM1
5 liver/biliary system MP:0005370 9.86 ACE ALB APOA1 APOB APOE IL6
6 neoplasm MP:0002006 9.43 ACE ALB CPB2 ICAM1 IL6 SERPINE1
7 renal/urinary system MP:0005367 9.17 ACE ALB APOE CPB2 IL6 PIK3C2A

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
3
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
4
Glucagon Approved Phase 4 16941-32-5
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8
Eplerenone Approved Phase 4 107724-20-9 150310 443872
9
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
10 Orange Approved Phase 4
11
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
12
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
13
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Adenosine Approved, Investigational Phase 4 58-61-7 60961
16
Edoxaban Approved Phase 4 480449-70-5
17
Fenofibrate Approved Phase 4 49562-28-9 3339
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
20
Ticagrelor Approved Phase 4 274693-27-5 9871419
21
Cangrelor Approved Phase 4 163706-06-7 9854012
22
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
25
Candesartan Experimental Phase 4 139481-59-7 2541
26 Nutrients Phase 4
27 Micronutrients Phase 4
28 Trace Elements Phase 4
29 Incretins Phase 4
30 Disinfectants Phase 4
31 Chlorhexidine gluconate Phase 4
32 Anti-Infective Agents, Local Phase 4
33 Nitric Oxide Donors Phase 4
34 diuretics Phase 4
35 Natriuretic Agents Phase 4
36 isosorbide-5-mononitrate Phase 4
37 Glucagon-Like Peptide 1 Phase 4
38 Hypoglycemic Agents Phase 4
39 Antihypertensive Agents Phase 4
40 cadexomer iodine Phase 4
41 Calamus Phase 4
42 Diuretics, Potassium Sparing Phase 4
43 Mineralocorticoid Receptor Antagonists Phase 4
44 Mineralocorticoids Phase 4
45 Antioxidants Phase 4
46 Alpha-lipoic Acid Phase 4
47 carnitine Phase 4
48 Thioctic Acid Phase 4
49 Angiotensinogen Phase 4
50 Angiotensin II Type 1 Receptor Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 485)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery Unknown status NCT01133015 Phase 4
2 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
3 Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) Unknown status NCT01278186 Phase 4
4 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
5 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
6 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
7 A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
8 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study) Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
9 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
10 EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease. Completed NCT00531011 Phase 4
11 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
12 Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients Completed NCT01490398 Phase 4 Rosuvastatin
13 Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery Completed NCT00375063 Phase 4
14 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
15 A Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients Completed NCT00755443 Phase 4
16 Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels Completed NCT02602600 Phase 4 Liraglutide
17 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
18 Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
19 Assessment of Coronary Flow Reserve and CT Angiography By Hybrid PET/CT: Relation to Clinically Indicated SPECT Studies Completed NCT00320931 Phase 4
20 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
21 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
22 Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
23 (RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients Completed NCT02880137 Phase 4 Perflutren Lipid Microsphere
24 Model Project for the Reduction of Coronary Restenosis Completed NCT00627900 Phase 4
25 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
26 A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease Completed NCT00187889 Phase 4 Eplerenone;Placebo or sugar pill
27 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
28 Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis Completed NCT00180583 Phase 4
29 Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease Completed NCT00995423 Phase 4
30 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
31 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4
32 A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation Completed NCT02140801 Phase 4 Ticagrelor;Clopidogrel
33 Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT01186107 Phase 4
34 Randomized Comparison of Everolimus- Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
35 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
36 Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study Completed NCT01272895 Phase 4
37 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
38 Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial) Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
39 Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography Completed NCT02120859 Phase 4
40 Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients Completed NCT00494559 Phase 4 Pioglitazone;Placebo
41 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
42 Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography Completed NCT01056744 Phase 4
43 Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation Completed NCT00139386 Phase 4 Candesartan
44 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
45 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
46 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study Completed NCT00349895 Phase 4
47 Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
48 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
49 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial Recruiting NCT02601157 Phase 4 3-months DAPT;1-year DAPT
50 A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease Recruiting NCT03718559 Phase 4 Edoxaban;Single Antiplatelet Agents

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

41
Heart, Testes, Endothelial, Kidney, Liver, Neutrophil, Lung

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 8187)
# Title Authors PMID Year
1
The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. 9 38
19551315 2009
2
[Lipoprotein (a), D-Dimer and apolipoprotein A1 as markers of presence and severity of coronary disease]. 9 38
19386322 2009
3
Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. 9 38
18403458 2008
4
[Level of alpha-granule membrane protein (CD62P) in coronary heart disease]. 9 38
18353216 2008
5
[Association between plasma adiponectin levels and coronary lesion complexity]. 9 38
18087549 2007
6
[Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis]. 9 38
17524316 2007
7
The 3'-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. 9 38
16829343 2006
8
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. 9 38
16084515 2006
9
Cholesteryl ester transfer protein gene polymorphisms and severity of coronary stenosis. 9 38
16553359 2006
10
Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. 9 38
15756041 2005
11
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. 9 38
15488875 2004
12
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. 9 38
15495786 2004
13
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFalphaRII in patients with coronary artery disease. 9 38
14603993 2003
14
[Lipoprotein (a)--a mysterious factor in atherogenesis]. 9 38
12679978 2002
15
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. 9 38
11171785 2001
16
Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. 9 38
10487496 1999
17
Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death. 9 38
10335875 1999
18
Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. 9 38
9242969 1997
19
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. 9 38
8960946 1996
20
Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis. 9 38
8803721 1996
21
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. 9 38
7686453 1993
22
Hemodynamic impact of coronary stenosis using computed tomography: comparison between noninvasive fractional flow reserve and 3D fusion of coronary angiography with stress myocardial perfusion. 38
31073698 2019
23
Characteristics of coronary artery atherosclerotic plaques in chronic kidney disease: evaluation with coronary CT angiography. 38
31285036 2019
24
[Invasive physiological evaluation of coronary artery disease]. 38
31070312 2019
25
Circulating microRNAs in suspected stable coronary artery disease: A coronary computed tomography angiography study. 38
31141242 2019
26
Current mechanisms of low graft flow and conduit choice for the right coronary artery based on the severity of native coronary stenosis and myocardial flow demand. 38
30737658 2019
27
Undilatable Calcific Coronary Stenosis Causing Stent Underexpansion and Late Stent Thrombosis: A Complex Scenario Successfully Managed With Intravascular Lithotripsy. 38
30981572 2019
28
The many faces of myocardial ischaemia and angina. 38
31228187 2019
29
Diagnostic value of stress thallium-201/rest technetium-99m-sestamibi sequential dual isotope high-speed myocardial perfusion imaging for the detection of haemodynamically relevant coronary artery stenosis. 38
29380286 2019
30
Image quality and diagnostic accuracy of coronary CT angiography derived from low-dose dynamic CT myocardial perfusion: a feasibility study with comparison to invasive coronary angiography. 38
30413956 2019
31
Fractional flow reserve in patients with reduced ejection fraction. 38
31419282 2019
32
Two years clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study. 38
31402574 2019
33
Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis. 38
31125259 2019
34
Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. 38
31386900 2019
35
Familial hypercholesterolemia with early coronary atherosclerotic heart disease: A case report. 38
31316595 2019
36
Development of a Porcine Model of Coronary Stenosis Using Fully Percutaneous Techniques Suitable For Performing Cardiac Computed Tomography, CT-Perfusion Imaging and Fractional Flow Reserve. 38
30054125 2019
37
Prevalence of Subclinical Atherosclerosis and Risk of Atherosclerotic Cardiovascular Disease in Older Adults Living with HIV. 38
31382762 2019
38
Prediction of Coronary Revascularization in Stable Angina: Comparison of FFRCT With CMR Stress Perfusion Imaging. 38
31422146 2019
39
Contemporary differences between men and women with acute coronary syndromes: CIAM multicenter registry. 38
31260420 2019
40
Utility and Validity of Intracoronary Administration of Nicorandil Alone for the Measurement of Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis. 38
31413232 2019
41
Turn-to-Shockable Rhythm Has Comparable Neurologic Outcomes to Initial Shockable Rhythm in Out-of-Hospital Cardiac Arrest Patients Who Underwent Targeted Temperature Management. 38
31411544 2019
42
The relationship between the carotid and coronary artery stenosis: a study based on angiography. 38
31131734 2019
43
Evolution of our understanding of the aVR sign. 38
31401390 2019
44
Functional Significance of Coronary Stenosis: Is it About the Real or Virtual Physiology? 38
30343081 2019
45
A wide range gate data acquisition for diagnosing coronary artery disease. 38
31403732 2019
46
Exercise and pharmacologic stress-induced interlead T-wave heterogeneity analysis to detect clinically significant coronary artery stenosis. 38
31412992 2019
47
Integrated quadruple stress echocardiography. 38
29642694 2019
48
Plaque Volume and Morphology are Associated with Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography. 38
30568077 2019
49
Association of coronary artery calcium score with calcification and degree of stenosis: An autopsy study. 38
31427553 2019
50
The association between serum angiogenin and osteopontin levels and coronary collateral circulation in patients with chronic total occlusion. 38
31375653 2019

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.17 PCSK9 CETP APOE APOB APOA1 ALB
2 11.73 TNNI3 APOE APOA1 ALB
3 11.61 SERPINE1 IL6 ICAM1
4
Show member pathways
11.57 APOE APOB APOA1 ALB
5
Show member pathways
11.56 SERPINE1 IL6 ICAM1 CRP APOE APOB
6
Show member pathways
11.43 PCSK9 CETP APOE APOB APOA1
7 11.26 IL6 ICAM1 APOB
8 11.11 IL6 ICAM1 APOA1
9 10.74 IL6 CRP

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.93 VWF SERPINE1 PON1 PIK3C2A ICAM1 CPB2
2 collagen-containing extracellular matrix GO:0062023 9.89 VWF SERPINE1 ICAM1 APOE APOA1
3 early endosome GO:0005769 9.86 PCSK9 APOE APOB APOA1
4 endoplasmic reticulum lumen GO:0005788 9.85 PCSK9 IL6 APOE APOB APOA1 ALB
5 blood microparticle GO:0072562 9.83 PON1 APOE APOA1 ALB
6 extracellular region GO:0005576 9.8 VWF SERPINE1 PON1 PCSK9 NPPB IL6
7 platelet alpha granule lumen GO:0031093 9.71 VWF SERPINE1 ALB
8 very-low-density lipoprotein particle GO:0034361 9.65 APOE APOB APOA1
9 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
10 low-density lipoprotein particle GO:0034362 9.61 APOE APOB APOA1
11 chylomicron GO:0042627 9.58 APOE APOB APOA1
12 high-density lipoprotein particle GO:0034364 9.56 PON1 CETP APOE APOA1
13 spherical high-density lipoprotein particle GO:0034366 9.55 PON1 APOA1
14 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
15 intermediate-density lipoprotein particle GO:0034363 9.5 APOE APOB APOA1
16 extracellular space GO:0005615 9.47 SERPINE1 PON1 PCSK9 NPPB IL6 ICAM1

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.97 PCSK9 IL6 APOE APOB APOA1 ALB
2 receptor-mediated endocytosis GO:0006898 9.93 APOE APOB APOA1 ALB
3 lipid transport GO:0006869 9.9 CETP APOE APOB APOA1
4 platelet degranulation GO:0002576 9.89 VWF SERPINE1 APOA1 ALB
5 retinoid metabolic process GO:0001523 9.8 APOE APOB APOA1
6 steroid metabolic process GO:0008202 9.8 PCSK9 CETP APOE APOB APOA1
7 cellular protein metabolic process GO:0044267 9.8 PCSK9 IL6 APOE APOB APOA1 ALB
8 triglyceride metabolic process GO:0006641 9.79 PCSK9 CETP APOE
9 triglyceride homeostasis GO:0070328 9.76 CETP APOE APOA1
10 triglyceride catabolic process GO:0019433 9.73 APOE APOB APOA1
11 cholesterol transport GO:0030301 9.72 CETP APOB APOA1
12 cholesterol efflux GO:0033344 9.71 APOE APOB APOA1
13 positive regulation of lipid biosynthetic process GO:0046889 9.7 APOE APOA1
14 reverse cholesterol transport GO:0043691 9.7 CETP APOE APOA1
15 positive regulation of cholesterol efflux GO:0010875 9.69 PON1 APOE
16 negative regulation of blood coagulation GO:0030195 9.69 SERPINE1 APOE
17 heart contraction GO:0060047 9.69 TNNI3 ACE
18 low-density lipoprotein particle remodeling GO:0034374 9.69 CETP APOE APOB
19 regulation of blood vessel diameter GO:0097746 9.68 NPPB ACE
20 phosphatidylcholine metabolic process GO:0046470 9.68 PON1 CETP
21 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 CRP CETP
22 high-density lipoprotein particle assembly GO:0034380 9.68 APOE APOA1
23 phospholipid efflux GO:0033700 9.67 APOE APOA1
24 phospholipid homeostasis GO:0055091 9.67 CETP APOA1
25 negative regulation of fibrinolysis GO:0051918 9.67 SERPINE1 CPB2
26 high-density lipoprotein particle clearance GO:0034384 9.66 APOE APOA1
27 positive regulation of cholesterol esterification GO:0010873 9.66 APOE APOA1
28 negative regulation of lipid storage GO:0010888 9.65 IL6 CRP
29 neutrophil mediated immunity GO:0002446 9.65 IL6 ACE
30 chylomicron remnant clearance GO:0034382 9.65 APOE APOB
31 chylomicron assembly GO:0034378 9.65 APOE APOB APOA1
32 cholesterol homeostasis GO:0042632 9.65 PCSK9 CETP APOE APOB APOA1
33 regulation of cholesterol transport GO:0032374 9.64 APOE APOA1
34 regulation of Cdc42 protein signal transduction GO:0032489 9.64 APOE APOA1
35 very-low-density lipoprotein particle remodeling GO:0034372 9.63 CETP APOE APOA1
36 very-low-density lipoprotein particle clearance GO:0034447 9.62 APOE APOB
37 negative regulation of plasminogen activation GO:0010757 9.62 SERPINE1 CPB2
38 lipoprotein catabolic process GO:0042159 9.61 APOE APOB
39 chylomicron remodeling GO:0034371 9.61 APOE APOB APOA1
40 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.58 PCSK9 APOE
41 lipoprotein biosynthetic process GO:0042158 9.54 APOE APOB APOA1
42 lipoprotein metabolic process GO:0042157 9.46 PCSK9 APOE APOB APOA1
43 high-density lipoprotein particle remodeling GO:0034375 9.26 CETP APOE APOA1 ALB
44 cholesterol metabolic process GO:0008203 9.1 PON1 PCSK9 CETP APOE APOB APOA1
45 lipid metabolic process GO:0006629 10.04 PON1 PCSK9 CETP APOE APOB APOA1

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.62 CETP APOE APOA1 ALB
2 cholesterol binding GO:0015485 9.61 CETP APOE APOA1
3 phospholipid binding GO:0005543 9.56 PON1 APOE APOB APOA1
4 low-density lipoprotein particle binding GO:0030169 9.49 PCSK9 CRP
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.48 APOE APOA1
6 lipoprotein particle binding GO:0071813 9.46 APOE APOA1
7 lipid transporter activity GO:0005319 9.46 CETP APOE APOB APOA1
8 very-low-density lipoprotein particle receptor binding GO:0070326 9.4 PCSK9 APOE
9 apolipoprotein receptor binding GO:0034190 9.37 PCSK9 APOA1
10 low-density lipoprotein particle receptor binding GO:0050750 9.26 PCSK9 CRP APOE APOB
11 cholesterol transporter activity GO:0017127 8.92 CETP APOE APOB APOA1

Sources for Coronary Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....